Last reviewed · How we verify

NCT06631625

Effect of Addition of Dexmedetomidine or Ketamine to Intravenous Infusion of Lidocaine on Proinflammatory Cytokines in Pelvi-abdominal Cancer Surgeries.

Completed Phase 1 Last updated 8 October 2024
What this trial tests

Phase 1 trial testing Lidocaine Intravenous Infusion in Pelvic Cancer in 45 participants. Completed in 24 September 2024.

Timeline
24 September 2023
Primary endpoint
24 September 2024
24 September 2024

Quick facts

Lead sponsorAlexandria University
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposehealth services research
Enrollment45
Start date24 September 2023
Primary completion24 September 2024
Estimated completion24 September 2024
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Alexandria University

Who can join

Adults 40 to 70, any sex, with Pelvic Cancer or Abdominal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators hypothesize that effect of addition of dexmedetomidine or ketamine by IV infusion to lidocaine infusion may be more beneficial than lidocaine infusion alone on proinflammatory cytokines (IL-1, IL-6 and TNFα), and postoperative pain relief and decreased opioid consumption, reduced Length of stay.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Lidocaine Intravenous Infusion

Trials testing the same drug.

Other recruiting trials for Pelvic Cancer

Currently open trials in the same condition.

Other Alexandria University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06631625.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing